Portal hemodynamic effects of regorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study

Portal hemodynamic effects of regorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study - Portal hemodynamic effects of regorafenib

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029648

Enrollment

Registered

2017-11-01

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with advanced hepatocellular carcinoma

Interventions

Regorafenib 160 mg per day for 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced-stage HCC is confirmed by radiological analysis. Patients were classified as having advanced-stage HCC if they were not eligible for or had disease progression after surgical or locoregional therapies.

Exclusion criteria

Exclusion criteria: Tumor invasion in intrahepatic large vessels was classified according to the criteria of the Liver Cancer Study of Japan as portal tumor invasion involving first-order-branches (Vp3) and the main trunk of the portal vein (Vp4), or as tumor invasion involving first-order branches of the hepatic vein (Vv2) and the inferior vena cava (Vv3).

Design outcomes

Primary

Measure	Time frame
Changes in portal venous area	—

Countries

Japan

Contacts

Public ContactHisashi HIDAKA

Kitasato University School of Medicine Department of Gastroenterology, Internal Medicine

hisashi7@kitasato-u.ac.jp+81-42-778-7750

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026